Cargando…

Fecal microbiota and bile acids in IBD patients undergoing screening for colorectal cancer

Due to the potential role of the gut microbiota and bile acids in the pathogenesis of both inflammatory bowel disease (IBD) and sporadic colorectal cancer, we aimed to determine whether these factors were associated with colorectal cancer in IBD patients. 215 IBD patients and 51 non-IBD control subj...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lavelle, Aonghus, Nancey, Stéphane, Reimund, Jean-Marie, Laharie, David, Marteau, Philippe, Treton, Xavier, Allez, Matthieu, Roblin, Xavier, Malamut, Georgia, Oeuvray, Cyriane, Rolhion, Nathalie, Dray, Xavier, Rainteau, Dominique, Lamaziere, Antonin, Gauliard, Emilie, Kirchgesner, Julien, Beaugerie, Laurent, Seksik, Philippe, Peyrin-Biroulet, Laurent, Sokol, Harry
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176255/ https://www.ncbi.nlm.nih.gov/pubmed/35638103 http://dx.doi.org/10.1080/19490976.2022.2078620

Ejemplares similares

Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease
por: Buisson, Anthony, et al.
Publicado: (2021)

Rewiring the altered tryptophan metabolism as a novel therapeutic strategy in inflammatory bowel diseases
por: Michaudel, Chloé, et al.
Publicado: (2023)

Correction: Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
por: Rayer, Cassandra, et al.
Publicado: (2023)

Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
por: Cassandra, Rayer, et al.
Publicado: (2022)

Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study
por: Bouhnik, Yoram, et al.
Publicado: (2018)

Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study
por: Sokol, Harry, et al.
Publicado: (2020)

Clinical activity is an independent risk factor of ischemic heart and cerebrovascular arterial disease in patients with inflammatory bowel disease
por: Le Gall, Guillaume, et al.
Publicado: (2018)

Prevalence of Yersinia Species in the Ileum of Crohn's Disease Patients and Controls
por: Le Baut, Guillaume, et al.
Publicado: (2018)

Faster and less invasive tools to identify patients with ileal colonization by adherent‐invasive E. coli in Crohn's disease
por: Buisson, Anthony, et al.
Publicado: (2021)

Patient and Public Involvement in Research: Lessons for Inflammatory Bowel Disease
por: Honap, Sailish, et al.
Publicado: (2023)

Cost savings of anti-TNF therapy using a test-based strategy versus an empirical dose escalation in Crohn's disease patients who lose response to infliximab
por: Roblin, Xavier, et al.
Publicado: (2015)

SARS-CoV-2 infection in nonhuman primates alters the composition and functional activity of the gut microbiota
por: Sokol, Harry, et al.
Publicado: (2021)

Structural robustness of the gut mucosal microbiota is associated with Crohn's disease remission after surgery
por: Mondot, S, et al.
Publicado: (2016)

Use of imaging modalities for decision-making in inflammatory bowel disease
por: Nancey, Stéphane, et al.
Publicado: (2023)

Inter-kingdom effect on epithelial cells of the N-Acyl homoserine lactone 3-oxo-C12:2, a major quorum-sensing molecule from gut microbiota
por: Landman, Cécilia, et al.
Publicado: (2018)

Factors affecting outcomes in Crohn's disease over 15 years
por: Cosnes, Jacques, et al.
Publicado: (2012)

Su1499: IMMUNOMODULATORS ARE PROTECTIVE AGAINST SEVERE COVID 19: RESULTS FROM A LARGE MULTICENTRE COHORT OF INFLAMMATORY BOWEL DISEASE PATIENTS
por: Vuitton, Lucine, et al.
Publicado: (2022)

Su1490: COVID-19: A PREVALENCE RATE TWO TIMES LOWER THAN THAT OF THE GENERAL POPULATION IN FRENCH PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH INTRAVENOUS BIOLOGIC AGENTS
por: Lelong, Margaux, et al.
Publicado: (2022)

Distinct Postprandial Bile Acids Responses to a High-Calorie Diet in Men Volunteers Underscore Metabolically Healthy and Unhealthy Phenotypes
por: Lamaziere, Antonin, et al.
Publicado: (2020)

Risk of SARS-CoV-2 infection in healthcare workers with inflammatory bowel disease: a case-control study
por: Amiot, Aurelien, et al.
Publicado: (2022)

Butyrate acts through HDAC inhibition to enhance aryl hydrocarbon receptor activation by gut microbiota-derived ligands
por: Modoux, Morgane, et al.
Publicado: (2022)

Impact on Life Expectancy of Withdrawing Thiopurines in Patients with Crohn’s Disease in Sustained Clinical Remission: A Lifetime Risk-Benefit Analysis
por: Kirchgesner, Julien, et al.
Publicado: (2016)

Will the Quality of Research Remain the Same During the COVID-19 Pandemic?
por: Peyrin-Biroulet, Laurent
Publicado: (2020)

Development of the IBD Disk: A Visual Self-administered Tool for Assessing Disability in Inflammatory Bowel Diseases
por: Ghosh, Subrata, et al.
Publicado: (2017)

Genetic effects on the commensal microbiota in inflammatory bowel disease patients
por: Aschard, Hugues, et al.
Publicado: (2019)

Rotavirus-Like Particles: A Novel Nanocarrier for the Gut
por: Cortes-Perez, Naima G., et al.
Publicado: (2010)

Providing Guidance During a Global Viral Pandemic for the Care of Patients With Inflammatory Bowel Disease
por: Abreu, Maria T, et al.
Publicado: (2020)

Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise
por: Danese, Silvio, et al.
Publicado: (2021)

Evolution of IL-23 Blockade in Inflammatory Bowel Disease
por: Danese, Silvio, et al.
Publicado: (2022)

Review article: Updated management of acute severe ulcerative colitis: From steroids to novel medical strategies
por: Calméjane, Louis, et al.
Publicado: (2023)

Diurnal Interplay between Epithelium Physiology and Gut Microbiota as a Metronome for Orchestrating Immune and Metabolic Homeostasis
por: Martínez-García, Juan Jose, et al.
Publicado: (2022)

The risk of COVID-19 in IBD patients is increased by urban living and is not influenced by disease activity or intravenous biologics
por: Lelong, Margaux, et al.
Publicado: (2023)

Iron Deficiency in Patients with Inflammatory Bowel Diseases: A Prospective Multicenter Cross-Sectional Study
por: Peyrin-Biroulet, Laurent, et al.
Publicado: (2022)

Protecting patients with IBD during the COVID-19 pandemic
por: Fiorino, Gionata, et al.
Publicado: (2020)

Inflammatory Bowel Disease and COVID-19 Vaccination: A Patients’ Survey
por: Caron, Bénédicte, et al.
Publicado: (2021)

Anti-Inflammatory Effects of Analogues of N-Acyl Homoserine Lactones on Eukaryotic Cells
por: Peyrottes, Agathe, et al.
Publicado: (2020)

Oral Iron for IBD Patients: Lessons Learned at Time of COVID-19 Pandemic
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Reply
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Adaptive Designs: Lessons for Inflammatory Bowel Disease Trials
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Balancing Risks and Benefits in Inflammatory Bowel Disease Patients during the COVID-19 Pandemic
por: Kotze, Paulo Gustavo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_30mb3iut79ancrk1hoh5ljtu1d